Societe Generale’s Pacific Biosciences PACB Stock Holding History

Societe Generale’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$117K	Buy	+16,670	New	+$152K	﹤0.01%	2324

Other funds holding PACB

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Societe Generale's PACB Position: Q2 2016 in Review

Societe Generale opened a new position in Pacific Biosciences (PACB) in Q2 2016: 16,670 shares worth $117K. The stake represents ﹤0.01% of the portfolio and ranks #2324 among its holdings.

141 funds tracked by Wall St. Rank hold PACB as of Q2 2016.

Societe Generale held 16,670 shares of Pacific Biosciences worth $117K as of Q2 2016.
Pacific Biosciences was a new Societe Generale position in Q2 2016.
Pacific Biosciences made up ﹤0.01% of Societe Generale's portfolio in Q2 2016, its #2324 holding.
141 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2016.

Based on Societe Generale's 13F filing for Q2 2016, filed 2 Aug 2016.